0001193125-20-241518.txt : 20200909 0001193125-20-241518.hdr.sgml : 20200909 20200909071358 ACCESSION NUMBER: 0001193125-20-241518 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200909 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200909 DATE AS OF CHANGE: 20200909 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 201165382 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 8-K 1 d54593d8k.htm 8-K 8-K
NY false 0001567514 0001567514 2020-09-09 2020-09-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2020

 

 

Intra-Cellular Therapies, Inc.

(Exact name of registrant as specified in its charter)

 

 

Commission File Number: 001-36274

 

Delaware   36-4742850

(State or other jurisdiction

of incorporation)

  

(IRS Employer

Identification No.)

430 East 29th Street

New York, NY 10016

(Address of principal executive offices, including zip code)

(646) 440-9333

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading Symbol(s)

  

Name of each exchange on which registered

Common Stock   ITCI   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

ITEM 8.01

Other Events.

On September 9, 2020, Intra-Cellular Therapies, Inc. (the “Company”) announced positive topline results from its Phase 3 clinical trial (Study 402) evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.

The Company’s press release announcing positive topline results from its Phase 3 clinical trial (Study 402) is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

ITEM 9.01

Financial Statements and Exhibits.

 

(d)

Exhibits

 

Exhibit

Number

   

Description

99.1    Press release dated September 9, 2020
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

The press release may contain hypertext links to information on our website. The information on our website is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

INTRA-CELLULAR THERAPIES, INC.
By:  

/s/ Lawrence J. Hineline

  Lawrence J. Hineline
  Senior Vice President of Finance, Chief Financial Officer, Treasurer and Assistant Secretary

Date: September 9, 2020

EX-99.1 2 d54593dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Intra-Cellular Therapies Announces Positive Topline Results

from Study 402 Evaluating Lumateperone

as Adjunctive Therapy in Patients with Bipolar

Depression

Lumateperone 42 mg achieved statistically significant results in primary and key secondary endpoints in Study 402. Company expects to submit supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) in late 2020 or early 2021.

Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo (p=0.0206).

Lumateperone 42 mg also met the key secondary objective on the Clinical Global Impression Scale for Bipolar for Severity of Illness- Depression subscale (CGI-BP-S) (p=0.0082).

Favorable safety and tolerability profile observed, consistent with all prior lumateperone trials. Rates of akathisia, restlessness, extrapyramidal symptoms and changes in weight were similar to placebo.

This study, in conjunction with our previously reported positive Phase 3 monotherapy study, Study 404, forms the basis for our sNDA for the treatment of bipolar depression in patients with Bipolar I or II disorder as monotherapy and adjunctive therapy.

Conference call scheduled today at 8:00 a.m. ET

NEW YORK, September 9, 2020 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced

positive topline results from its Phase 3 clinical trial (Study 402) evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. In Study 402, once daily lumateperone 42 mg met the primary endpoint for improvement in depression as measured by change from baseline versus placebo on the MADRS total score (p=0.0206; effect size = 0.27). Lumateperone 42 mg also met the key secondary endpoint, the CGI-BP-S Depression Score (p=0.0082; effect size = 0.31). The lower lumateperone dose, 28 mg, showed a trend for a dose-related improvement in symptoms of depression but the results did not reach statistical significance. Lumateperone demonstrated a favorable safety profile and was generally well-tolerated in the trial. The most commonly reported adverse events that were observed at a rate greater than or equal to 5% and at least twice the rate of placebo were somnolence, dizziness, and nausea. Rates of akathisia, restlessness, extrapyramidal symptoms, and changes in weight were similar to placebo. This trial, in conjunction with our previously reported positive Phase 3 monotherapy study, Study 404, forms the basis for our sNDA for the treatment of bipolar depression in patients with Bipolar I or II disorder as monotherapy and adjunctive therapy which we expect to submit to the FDA in late 2020 or early 2021.

“Our program now has confirmatory evidence of efficacy and a favorable safety and tolerability profile of lumateperone in bipolar depression; we look forward to submitting our supplemental NDA to expand lumateperone’s label to include a second major neuropsychiatric disorder,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “With this clinical milestone, lumateperone has shown further potential to benefit patients suffering from a range of serious mental health conditions in addition to schizophrenia.”

“Bipolar disorders are serious and complex mental health conditions that affect millions of people, and depression is the most common presentation of these disorders. In this study, lumateperone demonstrated a robust effect, which is particularly significant considering patients were maintained on lithium or valproate,” said Dr. Roger McIntyre, Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. “Lumateperone is the first treatment to demonstrate efficacy for bipolar depression as monotherapy and as adjunctive therapy to mood stabilizers in a study population including both Bipolar I and Bipolar II patients. This will be welcome news to the psychiatric community as there is a tremendous need for improved treatment options.”

About Study 402

Study 402 was conducted globally in five countries including in the U.S. A total of 529 patients with moderate to severe major depressive episodes associated with either Bipolar I or Bipolar II disorder were randomized 1:1:1 to lumateperone 42 mg, 28 mg or placebo, while being maintained on lithium or valproate as mood stabilizers.

Lumateperone 42 mg met the primary endpoint by demonstrating a statistically significant improvement compared to placebo at week 6 (trial endpoint), as measured by change from baseline on the MADRS total score. In the intent-to-treat (ITT) study population, the least squares (LS) mean reduction from baseline for lumateperone 42 mg was 16.9 points, versus 14.5 points for placebo (LS mean difference = 2.4 points; effect size = 0.27, p=0.0206).

Lumateperone 42 mg also met the key secondary endpoint of statistically significant improvement on the CGI-BP-S Depression Score (p=0.0082; effect size = 0.31).

Lumateperone 28 mg showed a trend for a dose-related improvement in symptoms of depression. Though not formally tested against placebo since it did not separate on the primary endpoint, lumateperone 28 mg demonstrated a statistically significant improvement versus placebo on the CGI-BP-S.

Lumateperone was generally well-tolerated with a favorable safety profile in the trial. Adverse events were mostly mild to moderate and similar to those seen in prior studies in bipolar depression and schizophrenia, with no new adverse events observed. These findings provide further evidence supporting lumateperone’s favorable safety and tolerability profile across different patient populations.

Conference Call and Webcast Details

Intra-Cellular Therapies will host a live conference call and webcast today at 8:00 a.m. ET, during which management will discuss the topline results of Study 402. The live webcast and subsequent replay may be accessed by visiting the Company’s website at www.intracellulartherapies.com. Please connect to the Company’s website at least 5-10 minutes prior to the live webcast to ensure adequate time for any necessary software download.

Alternatively, please call 1-(844) 835-6563 (U.S.) or 1-(970) 315-3916 (international) to listen to the live conference call. The conference ID number for the live call is 2980818. Please dial in approximately 10 minutes prior to the call.

About Lumateperone

Pharmacodynamics studies have shown lumateperone acts as a potent antagonist with high binding affinity at serotonin 5-HT2A receptors, as an antagonist with moderate binding affinity at postsynaptic D2 receptors, an inhibitor of the reuptake of serotonin transporter (SERT) with moderate biding affinity, and a partial agonist with moderate affinity at D1 receptors (which may contribute to the indirect activation of AMPA and NMDA receptors). These receptors are believed to play an important role in in schizophrenia, bipolar disorder, depressive disorders and other neuropsychiatric disorders. In vitro studies have shown lumateperone has a ~60-fold greater affinity for 5-HT2A receptors compared to D2 receptors.

Lumateperone is being investigated for the treatment of bipolar depression, depression and other neuropsychiatric and neurological disorders. Lumateperone is not FDA approved for these disorders. CAPLYTA 42 mg (lumateperone) is approved by the FDA for the treatment schizophrenia of adults.

About Bipolar Depression

Bipolar I and Bipolar II disorder are serious, highly prevalent psychiatric conditions, affecting approximately 6 million adults in the United States, or about 2.8% of the U.S. population.

These disorders are characterized by recurrent episodes of mania or hypomania interspersed with episodes of major depression known as Bipolar depression. Bipolar I and Bipolar II each represent about half of the overall population of patients with bipolar disorder.

Bipolar depression is the most common clinical presentation of bipolar disorder. These episodes tend to last longer, recur more often, and are associated with a worse prognosis than the manic/hypomanic episodes. Bipolar depression remains a significantly underserved medical need, with only a few FDA-approved treatment options available. These treatments are commonly associated with tolerability issues.

About Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the safety, tolerability and efficacy of our product candidates; the potential for lumateperone to receive FDA approval for treatment of bipolar depression in patients with Bipolar I or II disorder as monotherapy and adjunctive therapy; our expectation that we will submit an sNDA, based on Study 402 and Study 404, for the treatment of bipolar depression in patients with Bipolar I or II disorder as monotherapy and adjunctive therapy to the FDA in late 2020 or early 2021; the potential for lumateperone to represent an advancement for the treatment of bipolar depression; and development efforts and plans under the caption “About Intra-Cellular Therapies.” All such forward-looking statements are based on management’s present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the following: we may encounter issues or other challenges in commercializing CAPLYTA for the treatment of schizophrenia, including but not limited to negative impacts from the COVID-19 pandemic, ongoing pricing negotiations with certain payors that have not finalized their assessments, and performance of our sales activity, and that results achieved in CAPLYTA in the treatment of schizophrenia may be different than observed in clinical trials and may vary among patients; any other impacts on our business as a result of or related to the COVID-19 pandemic; there can be no guarantee that the sNDA for lumateperone for the treatment of bipolar depression will be submitted within the target timelines

or that the sNDA will be approved by the FDA without a request for the submission of additional information or at all; and the other risk factors detailed in our public filings with the Securities and Exchange Commission. All statements contained in this press release are made only as of the date of this press release, and we do not intend to update this information unless required by law.

Contact:

Intra-Cellular Therapies, Inc.

Juan Sanchez, M.D.

Vice President, Corporate Communications and Investor Relations

646-440-9333

Burns McClellan, Inc.

Lisa Burns

jgrimaldi@burnsmc.com

212-213-0006

MEDIA INQUIRIES:

Ana Fullmer

Corporate Media Relations W2Owcg

afullmer@wcgworld.com

202-507-0130

EX-101.SCH 3 itci-20200909.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 itci-20200909_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Address, State or Province Entity Address, State or Province Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 itci-20200909_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g54593g0909080608300.jpg GRAPHIC begin 644 g54593g0909080608300.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^LW5]=L- M$@\R\G520=J9Y;%1^(M=@\/Z5)=R_,^,1IGEC7BA;5?%NL[QYN.Q_L&J=-7DSM;WXJ@2'[%:*4[>9G-%E\5WO3J*TD:E%%%9'I!1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% 'C?Q)U1M0\0I8QG,=L-F,_P 9//\ 2N\\#^'H]&T2*1XQ]JG7 M?(QZC/:O,8(SJWQ "R98S718_AS_ $KW4 #H*Z*KY8J*/#RZ'MJ]3$2[V0 MM%%%H33+"N6.,G KA/$GBB]\.ZI%)YJRVY8>8@'45K&3<>4\S%4*<*RQ-[-;G?U MC7>N&V\16NE^3N$Z;M^>G-:L$R7-O'-&*ZG3=1BOM,M[OGB%.3@TT_,=J>I6^DV$MY=-MCC&3[URR>(O$.H(;BRTH+;@G;O)!< M>O2G>+674-:T;3"P:"27?*H/##_.*[%55$"* % P .U5I%)V,GSUZDHQE91[ M=65[">:YL(9IXO*E= 63^Z?2K#'"D^@KG=>U6]_M*WT;2R@NIU+R.W_+-/6J MEA?:GI6O1Z/JDZ3Q7,9-O*!@DCJ*7)=7*^LQC+D=W;2_2Y77Q+J#>&=:OLIY MUHY6+CBNKTN=[K2[6>3[\D2LWU(KSU/^1(\3?]=6_G6Z-7NK%O#MI#M\JYB4 M29'/3M5RC?8Y,/B'%IS;:LOQDT=A7/0:M=/XRGTQBOV=(PPXYSBCQ5JUUI(T MMK8K^_O4A<,.JGK5&V_Y*/=?]1A'I)7^:9U]%<7JR>)+& M*XU3[?"/)+,MN1P4']<4NM^*KJWT'2]3LT'^E$;D(R2,CI2]FWL-XR,;\Z:M MK\MCLZ*Y6SM/$DUN);JXC25SNVKT ["BCE7(P)9 ' [,.M74] MZ*D<67KV-:I0?>Z]#3HHHK$]8PO%D-V^ARRV0)GA^=5'?UKQ2ZFU3Q)J45FL M$IF=@N&4_+]:]XUO5(M&TF>]E(Q&O /<]JXCP9XFOMTM-+''AO M;G\ZVA?E;/(QT83K1IN33?0[[3[466GP6P.?+0+FN9U3_DH.E_\ 7(_SKKZS MI]&M[C6(-3DY0C&/1K\&87A+_D/^(O^OA?Y&HK;_D? M-6_Z]*Z+3]&M]-O+RYA+;[M@\@)[BDBT6VAUF;4U+>=,FQP3QBJ#)K@+DQM(V/7DU>M/"-O9 M:M->6]Q*D$'Y22"/ZUHZ;HMKI>F-80@M"V[.XYSGK3E*.OF11H58\MU; ME37Y69P_]FKJ_A2XUS5=1D,DR,Z1K)A(SV7^5;&D:!#K'AC37FFFB*QXQ&V! MU/\ C4J> K("2%KF8V;$E8,_*"/#QT?48C)+!9RXF)Y;:>_YUVT%Y;W%NDT *ISTT9E'"M5>: M4+W=[WV_X8Y"/_D2/$W_ %U8_K5[476";PI<2';$%52QZ D5T8\+6(TN^T\, M_E7A)D.><^U2ZCX;LM3T>'39MWEP@>6P/*XHYU[US4 M]0D9I(W>*-7PJ>@(]>*B?!\)>%QU&\5T \"60DF0W,_V21BWV?=\H)ZUH'PO M8FPL;/,GE69S%SS^-5SQ,5@ZK3O&SM;?=W3N;:_='THI1P,45@>R9VMV@O-- MEB:$3QE?FB/\0]O>O/M&6_\ #-VUSI9:^TF1OWL(^_%ZY'K7J5L]2C0QL4D;@QL.0?>K5 M[?VNGVS3W4RQ1J.2QKS&]G\<:82A4/SCS8U S64-&\5^)+@"Y\S!."SG"_B! M5^R6]]#F>95$N10;EZ6#QAXIF\37ZV=H&^R(^(T'\;>M>B>!_#O]@Z/F4#[3 M.0SG'('856\+> [712MS=8FN^",\A#[5V-*I-6Y8[%X+!U/:/$5_B?X!7->* M#JGS>U$6KZBK1GR)4][HA\,ZA+JFCBZE.2TC@'V!P*K^+=0N-.T^%[>;RC)* M$9_08J_HNF_V58?9MV?WC/\ FK/\ %%_+8VD!CG\@22!6DS]T9%:MDDT=HBW 42#K MM/'\A5;5-,&I&WW$;8I ^#WY'_UZ2:YM2ZD9NCRQW(O#E]<:AI*3W&"9]Z)GA/6K6JV7]HZ;-:$X$H )]L@FAVYO( M(JI]7L_BLS)\,:C6]W9DEE*TUC;RO]YXU8_4 MBN<\1ZA*Z6VA^SVL,.<^6@7/T%8^K:3=7.J07UJZ M;HTV%7Q@]?8^M.-N8FO&;I)1WT_X)N)]Q><\=:YO7-1NH-:M;8W'V2T8 ^=G M&]O[M=(F=@W=>]8NO:5>:L%MXY%2V8#><\CW''6E&U]2L0ING[FYM#I121KL MC5,YV@#-%2="'4444 (0#U /UH Z #Z444"ZBT444#"BBB@ HHHH **** " >BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9 end XML 7 d54593d8k_htm.xml IDEA: XBRL DOCUMENT 0001567514 2020-09-09 2020-09-09 NY false 0001567514 8-K 2020-09-09 Intra-Cellular Therapies, Inc. 001-36274 DE 36-4742850 430 East 29th Street New York 10016 (646) 440-9333 false false false false Common Stock ITCI NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Sep. 09, 2020
Cover [Abstract]  
Entity Address, State or Province NY
Amendment Flag false
Entity Central Index Key 0001567514
Document Type 8-K
Document Period End Date Sep. 09, 2020
Entity Registrant Name Intra-Cellular Therapies, Inc.
Entity File Number 001-36274
Entity Incorporation State Country Code DE
Entity Tax Identification Number 36-4742850
Entity Address, Address Line One 430 East 29th Street
Entity Address, City or Town New York
Entity Address, Postal Zip Code 10016
City Area Code (646)
Local Phone Number 440-9333
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol ITCI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d54593d8k.htm d54593dex991.htm itci-20200909.xsd itci-20200909_lab.xml itci-20200909_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d54593d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d54593d8k.htm" ] }, "labelLink": { "local": [ "itci-20200909_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "itci-20200909_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "itci-20200909.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "itci", "nsuri": "http://www.intracellulartherapies.com/20200909", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d54593d8k.htm", "contextRef": "duration_2020-09-09_to_2020-09-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d54593d8k.htm", "contextRef": "duration_2020-09-09_to_2020-09-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200909/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-20-241518-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-241518-xbrl.zip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end